Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

TIER 2 SUPPLIERS P A N E L S F O R O F F - R O A D V E H I C L E S • Transfer OEM-approved materials from North America to manufacturers in Europe • Help manufacturers avoid cash flow issues on small lot orders • Managed REACH qualification for 10 OEM- approved materials • Optimized logistics so manufacturers could purchase small lots 10 engineered material and Masterbatch solutions KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION GLOBAL SERVICE Copyright © 2020, Avient Corporation LEARN MORE https://www.polyone.com/products/thermoplastic-elastomers/onflex-thermoplastic-elastomers

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Our goal was to generate organic sales growth with margin expansion, and we delivered both in 2024,” said Dr. Khandpur added, “In addition, our 2024 safety performance represented the safest year in company history and evidenced that we’ll continue to build upon the many proven foundational strengths of Avient as we execute our new strategy.” 2025 Outlook “As we shared at our Investor Day in December, we laid out a path to grow organic sales 100 – 200 basis points above GDP with margin expansion by intersecting high growth markets and secular trends with our technologies to create platforms that scale,” said Jamie Beggs, Senior Vice President and Chief Financial Officer, Avient Corporation. Rose Vice President, Corporate Communications Avient Corporation +1 440-930-3162 kyle.rose@avient.com 7 Attachment 1 Avient Corporation Summary of Condensed Consolidated Statements of Income (Unaudited) (In millions, except per share data) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Sales $ 746.5 $ 719.0 $ 3,240.4 $ 3,142.8 Operating income 85.6 43.1 329.3 196.8 Net income from continuing operations attributable to Avient shareholders 48.3 27.8 169.5 75.8 Diluted earnings per share from continuing operations attributable to Avient shareholders $ 0.52 $ 0.30 $ 1.84 $ 0.83 Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.